We have located links that may give you full text access.
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems 2018 September 15
1. Steady-state plasma concentrations of anticoagulants and the time since the previous administration in mainly outpatients with atrial fibrillation administered standard or reduced doses were analyzed for 110 elderly Japanese subjects (mean age, 76 years) treated with apixaban (2.5 or 5.0 mg twice daily), dabigatran etexilate (110 or 150 mg twice daily), edoxaban (30 or 60 mg once daily), or rivaroxaban (10 or 15 mg once daily) at one general hospital. 2. The pharmacokinetics in patients treated with standard and reduced doses of the four anticoagulants using liquid chromatography-tandem mass spectrometry were compared with the concentration ranges estimated using physiologically based pharmacokinetic modelling. Reduced doses of anticoagulants resulted in relatively small pharmacokinetic variations compared with the standard dose. 3. Statistical analyses revealed that renal impairment is likely not the sole determinant factor for high plasma concentrations of apixaban, dabigatran, edoxaban, and rivaroxaban. 4. Patients with atrial fibrillation should be treated with the correct doses of oral anticoagulants as specified in the package inserts (e.g., reduced doses for elderly patients, patients with low body weights, and in combination with P-glycoprotein inhibitor drugs) to avoid excessive or insufficient doses of direct oral anticoagulants.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app